A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-004, a Humanized Monoclonal Antibody, in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2015
At a glance
- Drugs Ontuxizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Morphotek
- 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Nov 2013 Planned end date changed from 1 Oct 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 18 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.